Rationale and Design of ENDEAVOR: A Sequential Phase 2b–3 Randomized Clinical Trial to Evaluate the Effect of Myeloperoxidase Inhibition on Symptoms and Exercise Capacity in Heart Failure with Preserved or Mildly Reduced Ejection Fraction

Abstract

ENDEAVOR is the first phase 2b-3 study to evaluate whether myeloperoxidase inhibition can improve symptoms and exercise capacity in patients with HFpEF/HFmrEF.